phenytoin has been researched along with Optic Neuritis in 11 studies
Optic Neuritis: Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized trial of phenytoin in acute optic neuritis (ON) demonstrated a 30% reduction in retinal nerve fiber layer (RNFL) loss with phenytoin versus placebo." | 9.41 | Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. ( Altmann, DR; Blennow, K; Giovannoni, G; Gnanapavan, S; Grant, D; Hickman, SJ; Kapoor, R; Kuhle, J; Leppert, D; Raftopoulos, R; Zetterberg, H, 2021) |
| "Phenytoin has been shown to reduce the peripapillary retinal nerve fiber layer (pRNFL) loss in optic neuritis (ON)." | 9.34 | Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis. ( Aghsaei Fard, M; Ghahvehchian, H; Gholizade, A; Yadegari, S, 2020) |
| " Patients with acute optic neuritis aged 18-60 years, presenting within 2 weeks of onset, with visual acuity of 6/9 or worse, were randomly assigned (1:1) by minimisation via a web-based service to oral phenytoin (maintenance dose 4 mg/kg per day if randomised before or on July 16, 2013, and 6 mg/kg per day if randomised on or after July 17, 2013) or placebo for 3 months, stratified by time from onset, centre, previous multiple sclerosis diagnosis, use of disease-modifying treatment, and use of corticosteroids for acute optic neuritis." | 9.22 | Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. ( Altmann, DR; Gandini Wheeler-Kingshott, CA; Giovannoni, G; Hickman, SJ; Hoggard, N; Kapoor, R; Koltzenburg, M; Malladi, P; Mallik, S; Miller, DH; Paling, D; Raftopoulos, R; Sarrigiannis, PG; Schmierer, K; Sharrack, B; Sheridan, R; Toosy, A; Yiannakas, MC, 2016) |
| "A randomized trial of phenytoin in acute optic neuritis (ON) demonstrated a 30% reduction in retinal nerve fiber layer (RNFL) loss with phenytoin versus placebo." | 5.41 | Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. ( Altmann, DR; Blennow, K; Giovannoni, G; Gnanapavan, S; Grant, D; Hickman, SJ; Kapoor, R; Kuhle, J; Leppert, D; Raftopoulos, R; Zetterberg, H, 2021) |
| "Phenytoin has been shown to reduce the peripapillary retinal nerve fiber layer (pRNFL) loss in optic neuritis (ON)." | 5.34 | Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis. ( Aghsaei Fard, M; Ghahvehchian, H; Gholizade, A; Yadegari, S, 2020) |
| " Patients with acute optic neuritis aged 18-60 years, presenting within 2 weeks of onset, with visual acuity of 6/9 or worse, were randomly assigned (1:1) by minimisation via a web-based service to oral phenytoin (maintenance dose 4 mg/kg per day if randomised before or on July 16, 2013, and 6 mg/kg per day if randomised on or after July 17, 2013) or placebo for 3 months, stratified by time from onset, centre, previous multiple sclerosis diagnosis, use of disease-modifying treatment, and use of corticosteroids for acute optic neuritis." | 5.22 | Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. ( Altmann, DR; Gandini Wheeler-Kingshott, CA; Giovannoni, G; Hickman, SJ; Hoggard, N; Kapoor, R; Koltzenburg, M; Malladi, P; Mallik, S; Miller, DH; Paling, D; Raftopoulos, R; Sarrigiannis, PG; Schmierer, K; Sharrack, B; Sheridan, R; Toosy, A; Yiannakas, MC, 2016) |
| "Phenytoin is a non-sedative barbiturate derivate and has been recently rediscovered as a neuroprotective and retinoprotective compound in patients affected by optic neuritis secondary to multiple sclerosis." | 4.98 | The retinoprotective role of phenytoin. ( Bartollino, S; Chiosi, F; Costagliola, C; di Staso, S; Hesselink, JMK; Pascotto, A; Rinaldi, M; Uva, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Yadegari, S | 1 |
| Gholizade, A | 1 |
| Ghahvehchian, H | 1 |
| Aghsaei Fard, M | 1 |
| Raftopoulos, R | 2 |
| Kuhle, J | 1 |
| Grant, D | 1 |
| Hickman, SJ | 2 |
| Altmann, DR | 2 |
| Leppert, D | 1 |
| Blennow, K | 1 |
| Zetterberg, H | 1 |
| Kapoor, R | 2 |
| Giovannoni, G | 2 |
| Gnanapavan, S | 1 |
| Chiosi, F | 2 |
| Keppel Hesselink, J | 1 |
| Rinaldi, M | 2 |
| Di Staso, S | 2 |
| Bartollino, S | 2 |
| Costagliola, C | 2 |
| Uva, M | 1 |
| Pascotto, A | 1 |
| Hesselink, JMK | 1 |
| Saidha, S | 1 |
| Calabresi, PA | 1 |
| Toosy, A | 1 |
| Sharrack, B | 1 |
| Mallik, S | 1 |
| Paling, D | 1 |
| Yiannakas, MC | 1 |
| Malladi, P | 1 |
| Sheridan, R | 1 |
| Sarrigiannis, PG | 1 |
| Hoggard, N | 1 |
| Koltzenburg, M | 1 |
| Gandini Wheeler-Kingshott, CA | 1 |
| Schmierer, K | 1 |
| Miller, DH | 1 |
| Addington, WW | 1 |
| Igata, A | 1 |
| Podos, SM | 2 |
| Keltner, JL | 2 |
| Becker, B | 1 |
| Gay, AJ | 1 |
| Ellenberger, C | 1 |
| Burde, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis[NCT01451593] | Phase 2 | 92 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phenytoin and Optic Neuritis
| Article | Year |
|---|---|
The retinoprotective role of phenytoin.
Topics: Antineoplastic Agents; Drug Discovery; Enzyme Inhibitors; Humans; Multiple Sclerosis; Neuroprotectiv | 2018 |
[Ataxia associated with infections and toxicosis].
Topics: Abdomen; Adult; Animals; Ataxia; Cerebellar Ataxia; Cerebrovascular Disorders; Demyelinating Disease | 1971 |
Glaucoma.
Topics: Acid-Base Equilibrium; Animals; Contact Lenses, Hydrophilic; Delayed-Action Preparations; Glaucoma; | 1973 |
4 trials available for phenytoin and Optic Neuritis
| Article | Year |
|---|---|
Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis.
Topics: Humans; Optic Neuritis; Phenytoin; Retina; Retinal Ganglion Cells; Tomography, Optical Coherence | 2020 |
Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis.
Topics: Biomarkers; Humans; Intermediate Filaments; Neurofilament Proteins; Neuroprotection; Optic Neuritis; | 2021 |
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Optic Neuriti | 2016 |
Acute optic neuropathy. Treatment with diphenylhydantoin.
Topics: Administration, Oral; Adult; Aged; Capsules; Female; Humans; Ischemia; Male; Middle Aged; Optic Nerv | 1974 |
4 other studies available for phenytoin and Optic Neuritis
| Article | Year |
|---|---|
Phenytoin: its potential as neuroprotective and retinoprotective drug.
Topics: Animals; Anticonvulsants; Humans; Neuroprotective Agents; Optic Neuritis; Phenytoin; Retina | 2018 |
Phenytoin in acute optic neuritis: neuroprotective or not?
Topics: Female; Humans; Male; Neuroprotective Agents; Optic Neuritis; Outcome Assessment, Health Care; Pheny | 2016 |
The side effects and interactions of antituberculosis drugs.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Central Nervous System Diseases; Chemical and Dru | 1979 |
Effect of diphenylhydantoin in ischemic optic neuritis.
Topics: Adult; Aged; Eye; Female; Fixation, Ocular; Follow-Up Studies; Humans; Ischemia; Kinetics; Male; Mid | 1972 |